Inogen (INGN) Total Non-Current Liabilities (2013 - 2026)
Inogen's (INGN) quarterly Total Non-Current Liabilities came in at $84.6 million in Q1 2026, down 10.19% year-on-year from $94.2 million in Q1 2025, and down 4.05% on a QoQ basis from $88.2 million in Q4 2025.
Inogen (INGN) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Inogen (INGN) has 14 years of Total Non-Current Liabilities data on file, last reported at $84.6 million in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities fell 10.19% year-over-year to $84.6 million in Q1 2026; TTM through Mar 2026 was $84.6 million, a 10.19% decrease from a year earlier, with the FY2025 full-year figure at $88.2 million, down 19.32% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $84.6 million, down from $88.2 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for INGN reached as high as $113.1 million in Q1 2024 and fell as low as $84.6 million in Q1 2026.
- Historically, Total Non-Current Liabilities has averaged $100.7 million across 5 years, with a median of $104.6 million in 2024.
- Across the five-year window, Total Non-Current Liabilities gained 26.64% in 2024 and dropped 19.32% in 2025, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $95.5 million in 2022, then rose by 12.58% to $107.5 million in 2023, then gained by 1.67% to $109.3 million in 2024, then fell by 19.32% to $88.2 million in 2025, then slipped by 4.05% to $84.6 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $84.6 million in Q1 2026, $88.2 million in Q4 2025, and $92.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 20.94 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 41.44 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 41.88 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 2.64 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 3.53 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 9.85 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 24.21 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 3.57 Bn |
| 10 | Inogen | 172.68 Mn | 62.51 Mn | 37.86 Mn | 84.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84.63 Mn |
| Dec 31, 2025 | 88.20 Mn |
| Sep 30, 2025 | 92.02 Mn |
| Jun 30, 2025 | 95.56 Mn |
| Mar 31, 2025 | 94.23 Mn |
| Dec 31, 2024 | 109.33 Mn |
| Sep 30, 2024 | 104.59 Mn |
| Jun 30, 2024 | 110.14 Mn |
| Mar 31, 2024 | 113.13 Mn |
| Dec 31, 2023 | 107.53 Mn |
| Sep 30, 2023 | 109.89 Mn |
| Jun 30, 2023 | 86.98 Mn |
| Mar 31, 2023 | 92.36 Mn |
| Dec 31, 2022 | 95.51 Mn |
| Sep 30, 2022 | 111.11 Mn |
| Jun 30, 2022 | 106.39 Mn |
| Mar 31, 2022 | 109.76 Mn |
| Dec 31, 2021 | 112.04 Mn |
| Sep 30, 2021 | 113.33 Mn |
| Jun 30, 2021 | 118.13 Mn |